A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson’s Disease
Sponsor:
Aptinyx
Brief Summary:
To evaluate the safety and tolerability of NYX-458 in mild cognitive impairments associated
with Parkinson’s disease and explore the potential benefit in cognition.
with Parkinson’s disease and explore the potential benefit in cognition.
Criteria
Inclusion Criteria:
– A primary diagnosis of mild cognitive impairment associated with Parkinson’s Disease
– Montreal Cognitive Assessment ≥ 17
– Modified Hoehn and Yahr Stage 1 to 3, Inclusive
– Stable anti-parkinsonian regimen
– Has a study partner who can accompany the subject at specified study visits
Exclusion Criteria:
– Clinically meaningful motor complications
– Meets criteria for dementia
– Current use of medications with primarily central nervous system activities
– Other clinically significant medical histories that may interfere with completing the
study.
Locations
- Aptinyx Clinical Site, Fresno, California, United States, 93710
- Aptinyx Clinical Site, Oxnard, California, United States, 93030
- Aptinyx Clinical Site, Pasadena, California, United States, 91105
- Aptinyx Clinical Site, Reseda, California, United States, 91335
- Aptinyx Clinical Site, Simi Valley, California, United States, 93065
